Chief Executive Officer at Adastra Pharmaceuticals Inc.
Scott is Chief Executive Officer and President of Adiso Therapeutics, Inc and possesses more than 35 years of successful industry leadership, serving as a senior executive in multiple different settings, including CEO and Board Director at both Fortune 500 pharmaceutical and emerging biotechnology companies. Among Mr. Megaffin’s many career leadership roles, he previously served as the CEO of Adastra Pharmaceuticals Inc., a pioneer in the pursuit of better treatment options for high unmet need cancers, where he led the company from early informative to clinical-stage advancement of first-in-class clinical programs, leading to its acquisition by Cothera Bioscience. Earlier, he served as a President of Churchill Pharmaceuticals, Inc., where he led organizational growth and clinical development of a fully differentiated oral oncology asset for metastatic castrate resistant prostate cancer, gaining FDA approval and resulting in a transaction to Sun Pharma. Mr. Megaffin has held global strategic and operational positions of increasing responsibility within Onconova, Schering-Plough, Yamanouchi, Pharmacia, and Bristol-Myers Squibb, including six global drug development programs resulting in regulatory approvals. He possesses far reaching knowledge in a broad number of therapeutic categories including oncology, anti-infectives, inflammation, pain, critical care, and virology. Mr. Megaffin currently serves as a member of the board of Adiso, Adastra and BioNJ.
Source: BioNJ on 01/18/2023
By accessing ExecAtlas, you can view bios, network, connections and references of industry leading executives like Scott Megaffin. More specifically, you'll be able to:
Access over 1,500,000 executive and board member profiles.
Example: Scott Megaffin